What did @beckalosesit actually say?
Technically, not much, at least not about Mounjaro. The entire spoken transcript is a riff on Snoop Dogg's "I Wanna Thank Me," used as a celebratory caption for a 13-week transformation update. There are no dosage claims, no side effect disclosures, no before-and-after numbers. What the video communicates is a feeling: pride, momentum, visible results. The implicit claim is that 13 weeks on tirzepatide (Mounjaro) produced a meaningful physical transformation worth celebrating publicly.
That framing matters. The creator is not stating facts. They are performing confidence. But on a platform where 10,000 people are watching a Mounjaro update, the performance itself functions as an endorsement, and it deserves scrutiny on those terms.
Does the science back up 13-week Mounjaro results?
Yes, broadly. Thirteen weeks is roughly the point where tirzepatide's clinical effects become visually apparent for many patients, and the trial data is genuinely strong. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) followed adults with obesity over 72 weeks and found participants on the highest dose (15 mg) lost an average of 20.9% of body weight. At the 12-to-16-week mark, weight loss was already meaningful, typically in the 5-8% range depending on dose escalation and individual response.
Tirzepatide works as a dual GIP and GLP-1 receptor agonist, a mechanism that appears to outperform single-agonist drugs like semaglutide in head-to-head comparisons (Frías et al., 2021, NEJM). So the idea that someone hitting 13 weeks might look and feel noticeably different? Plausible. Supported. Not hype.
What did they get wrong, or right?
They got the vibe right, even if they said nothing clinical. The 13-week milestone is real. Most patients who stay on tirzepatide through dose escalation and past the early GI adjustment period do report significant changes by this point. Credit where it is due.
What the video skips entirely is the part that matters for anyone watching and considering starting: side effects, the role of diet and behavior change, the cost barrier (Mounjaro lists around $1,000 per month without insurance or a manufacturer coupon), and the evidence that weight returns when the medication stops (Aronne et al., 2024, Obesity). A 10K-view update with zero context about any of those realities is not misinformation exactly, but it is incomplete in a way that shapes expectations for people who do not know to ask the questions.
What should you actually know?
Thirteen weeks is not the finish line. It is closer to the end of the beginning. SURMOUNT-1 ran 72 weeks for a reason. Early results can be dramatic, and they can also plateau. Individual response to tirzepatide varies significantly based on starting weight, dose reached, dietary habits, and metabolic factors that no social media update can capture.
The more important number is what happens at week 20, week 40, and after discontinuation. A 2023 SURMOUNT-4 extension study found that patients who stopped tirzepatide after 36 weeks regained about half their lost weight within a year. That is not a reason to avoid the medication. It is a reason to understand it as a long-term intervention, not a 13-week fix.
- Talk to a licensed provider before starting any GLP-1 medication.
- Ask specifically about dose escalation schedules and managing early GI side effects.
- Do not use a TikTok update as your primary source of treatment expectations.